Larimar Therapeutics
increases in levels observed in buccal cells cohort | Larimar Therapeutics
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
35 of 44
Similar slides by Larimar Therapeutics
See diffirences between slides (animation)
Investor Presentation
November 2023
increases in levels observed in skin cells cohort | Larimar Therapeutics
Investor Presentation
November 2023
dose dependent increases in levels observed in skin and buccal cells in phase | Larimar Therapeutics
Investor Presentation
November 2023
increases in levels in phase trial cohort | Larimar Therapeutics
Investor Presentation
November 2023
dose dependent increases in levels observed in skin and buccal cells in phase | Larimar Therapeutics
Related slides by other companies
Alkermes
Investor Day
March 2021
induced dose dependent selective expansion of circulating and cells cells fold change from cells fold change from fold change from provided greater expansion of cells and cells relative to subcutaneous intravenous once every days once every days natural killer regulatory cells tags | Alkermes
Dare Bioscience
Investor Presentation
February 2023
dare proof of concept dare | Dare Bioscience
ATAI
Investor Day
January 2022
change from in the overall composite score | ATAI
BioAtla
Investor Presentation
August 2023
change from in sum of target lesions | BioAtla
Other recent decks by Larimar Therapeutics
See all presentations (3 decks)
Results
November 2022
Investor Presentation
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights